Here is the honest bottom line. Macular degeneration is one of the few eye conditions where nutrition has real randomized evidence behind it, and also one where waiting can cost you central vision permanently. The AREDS and AREDS2 trials showed that a specific supplement formula slows progression in people who already have intermediate or advanced dry AMD. No Ayurvedic preparation has been tested that way for AMD, and none has been shown to restore lost central vision. If you have wet AMD, anti-VEGF injections are the treatment that saves sight, and every month of delay matters.
Complementary-care boundary: Ayurvedic eye care does not replace intravitreal anti-VEGF injections such as aflibercept, ranibizumab, or bevacizumab for wet (neovascular) AMD. It does not replace dilated retinal examination, optical coherence tomography, or fluorescein angiography. It does not replace the AREDS2 supplement formula when your retina specialist has recommended it, and it does not replace complement inhibitor therapy for geographic atrophy if you and your specialist have chosen that path. What integrative care can do is address the modifiable risk side of this disease, which in AMD is unusually substantial.
An Integrative Approach to the Drivers of Age-Related Macular Degeneration
Age-related macular degeneration is a disease of the macula, the small central region of the retina that handles reading, faces, and fine detail. It is the leading cause of irreversible central vision loss in older adults in high-income countries, and a systematic review projected roughly 288 million people affected worldwide by 2040. Most people with AMD have the dry form, in which waste deposits called drusen accumulate under the retina and the retinal pigment epithelium slowly thins. A minority develop wet AMD, in which abnormal vessels grow from the choroid and leak.
The reason an integrative conversation is worth having in AMD, and not simply a polite add-on, is that diet, smoking, blood pressure, body weight, and physical activity all carry measurable associations with progression. That is not true of every retinal disease. It is true here. A clinician who tells you nothing about food and habits in AMD is leaving something on the table.
At the same time, the honest framing is narrow. The evidence supports slowing progression in certain eyes, not reversing damage in any eye. Once photoreceptors in the fovea are gone, no diet, supplement, oil, or therapy regrows them. Our job is to be precise about which parts of this we can influence and which parts belong entirely to the retina specialist.
Why Age-Related Macular Degeneration Care Should Be Multi-Factorial
Two diseases wear one name
Dry and wet AMD behave differently enough that treating them as one condition leads to bad decisions. Dry AMD usually declines over years and has no injection therapy in its early and intermediate stages. Wet AMD can take useful central vision away in weeks. A plan built for one is wrong for the other, and a patient can have dry AMD in one eye and wet in the other at the same time.
Smoking is the strongest modifiable risk
Across pooled analyses of risk factors, current smoking stands out as the single most consistent modifiable association with AMD onset and progression. The effect appears dose related and diminishes after quitting, though not immediately. Any integrative plan that discusses turmeric before it discusses tobacco has its priorities inverted.
Diet quality is measurable, not vague
Adherence to a Mediterranean pattern has been linked to lower incidence of advanced AMD in pooled European cohorts, and to slower progression in a cohort followed with genetic risk data. These are observational findings, so they cannot prove causation, but they are consistent, biologically plausible, and they point to specific foods rather than to a philosophy.
Cardiovascular health and retinal health overlap
The choroid is a high-flow vascular bed. Hypertension, obesity, and poor cardiometabolic control appear repeatedly in AMD risk analyses. Managing blood pressure and weight will not undo drusen, but it belongs in the same conversation rather than in a separate one held by a different clinician who never sees your retinal images.
Monitoring behavior changes outcomes
In wet AMD, how quickly you notice a change and act on it determines how much vision you keep. A randomized trial of a home monitoring device found that structured monitoring detected choroidal neovascularization at better visual acuity than standard care alone. Habits around self-checking are therefore a clinical variable, not a soft one.
Function matters as much as the retina
Reading, cooking, driving, and recognizing faces are what people actually lose. Low vision rehabilitation has randomized evidence supporting improvements in vision-related quality of life, and it is chronically underused. Care that only tracks letters on a chart misses most of what a person with AMD is dealing with day to day.
Key Biological Mechanisms in Age-Related Macular Degeneration
Retinal pigment epithelium overload
The retinal pigment epithelium recycles the tips of photoreceptor outer segments every day for decades. When that clearance slows, undigested material accumulates as lipofuscin inside the cells and as drusen beneath them. Drusen are not just markers. Their size and character predict how likely an eye is to progress, which is why your specialist grades them rather than simply noting their presence.
Oxidative stress in a light-saturated tissue
The macula combines intense light exposure, high oxygen tension, and membranes rich in polyunsaturated fatty acids. That combination generates reactive oxygen species continuously. This is the mechanistic rationale behind the antioxidant and zinc formula tested in the original AREDS trial, and it is the one place where a nutritional mechanism in eye disease has been carried all the way into a large randomized trial.
Macular pigment and short-wavelength light
Lutein and zeaxanthin are dietary carotenoids concentrated in the fovea, where they absorb short-wavelength light and quench free radicals. Supplementation raises macular pigment optical density in most people. Whether raising that number translates into preserved vision is a separate question, and the trial evidence on that point is narrower than the supplement marketing suggests.
Complement activation and geographic atrophy
Genetic and histologic work implicates the complement cascade in AMD, particularly in the advanced dry form called geographic atrophy. This is the biology behind the newer intravitreal complement inhibitors. They slow the enlargement of atrophic lesions on imaging; they do not restore vision within the atrophy, and the visual function benefit remains debated.
VEGF signaling and choroidal neovascularization
When the outer retina becomes hypoxic and stressed, vascular endothelial growth factor rises and new vessels grow through Bruch membrane from the choroid. These vessels leak fluid, blood, and lipid into and under the retina. Anti-VEGF drugs block that signal directly. This is why the injections work, and why stopping them often allows the process to restart.
Chronic low-grade inflammation
Para-inflammation at the retinal pigment epithelium and choroid interface, involving microglia and macrophages, appears to sustain the disease process between visible events. Diet, smoking status, and cardiometabolic health plausibly modulate this background state. This is the mechanism most often invoked for Ayurvedic and other botanical interventions, and it is worth saying clearly that plausibility at this level has not been converted into clinical trial evidence in AMD.
How Age-Related Macular Degeneration Presents and How It Progresses
Early AMD is usually silent
Small and medium drusen often cause no symptoms at all. They are found on a routine dilated exam, sometimes years before anything changes. This stage carries low short-term risk of vision loss, and the AREDS formula was not shown to help here. What it does earn you is a schedule of monitoring and a reason to take smoking and diet seriously now rather than later.
Intermediate AMD brings the first real complaints
Large drusen or pigment changes mark the intermediate stage. People describe needing more light to read, slower adjustment when walking from sunlight into a dim room, and print that looks faintly gray rather than crisp. This is the stage where the AREDS2 supplement discussion belongs, because that is the population the trials enrolled.
Geographic atrophy erodes vision in patches
In advanced dry AMD, well-defined areas of retinal pigment epithelium and photoreceptors die off. Patients often notice missing letters in the middle of words before they notice a blank spot, because the eye and brain fill in gaps. Reading speed falls before acuity does. Progression is measured in square millimeters per year on autofluorescence imaging.
Wet AMD announces itself with distortion
The classic first symptom of choroidal neovascularization is metamorphopsia: straight lines that bend, door frames that bow, faces that look warped on one side. It can appear over days. A sudden gray or dark central patch is the other common presentation. Either one is an urgent-visit symptom, not a wait-and-see symptom.
One eye hides the other
Because both eyes overlap in the central field, a person can lose a great deal in one eye and not register it until they happen to cover the good eye. This is the single most common reason people with AMD arrive late. Checking each eye separately, on a set schedule, is what converts a silent change into an early one.
The long arc is variable
Some people stay at intermediate AMD for a decade or more. Others convert to wet disease within a year. Drusen characteristics, pigment changes, the status of the fellow eye, smoking, and genetic factors all shift the odds. No one can tell you your personal timeline with confidence, which is exactly why monitoring is built around detection rather than prediction.
How Age-Related Macular Degeneration Is Assessed at Netra Eye Institute
Assessment has two jobs. The first is to establish what stage you are at and whether there is any sign of neovascular activity, because that determines urgency. The second is to map the modifiable factors that an integrative plan can actually work on. We do not perform intravitreal injections here, so part of every AMD assessment is making sure your retina specialist relationship is in place and current.
Best-corrected visual acuity and near reading
Distance acuity alone underestimates AMD disability. We measure best-corrected distance acuity, then near acuity and continuous reading performance, because reading fluency degrades earlier and tracks function better than a single line on a chart.
Amsler grid technique, taught properly
Most patients have been handed an Amsler grid and never shown how to use it. We check that you test one eye at a time with reading glasses on, at about 14 inches, fixating the central dot and noting any waviness, blur, or missing area. We ask you to test daily and to define in advance what would make you call.
Dilated fundus examination
A dilated look at the macula characterizes drusen size and number, pigment mottling, atrophy, and any hemorrhage or exudate. This is also where the fellow eye is graded, since fellow-eye status carries real weight in estimating risk.
Optical coherence tomography
OCT is the workhorse of AMD care. It shows drusen under the retinal pigment epithelium, the integrity of outer retinal layers, and, critically, intraretinal or subretinal fluid that indicates neovascular activity. If OCT raises any suspicion of fluid, the next call is to a retina specialist, not to us.
Fundus autofluorescence when atrophy is present
Autofluorescence imaging delineates geographic atrophy edges and highlights the hyperautofluorescent rim associated with faster enlargement. It gives a reproducible baseline against which progression can be judged over years rather than guessed at.
Angiography, arranged rather than performed
Fluorescein angiography and OCT angiography characterize neovascular membranes. These are retina-specialist studies. Our role is to recognize when they are needed and to make sure the referral happens the same week, not the same month.
Systemic and nutritional review
We record smoking history in pack-years, blood pressure, body mass index, lipid and glucose status, and a structured dietary intake covering leafy greens, colored vegetables, fish, nuts, olive oil, and processed food frequency. We also record every supplement and its actual dose, which is often not what the label implies.
Medication, allergy, and Ayurvedic preparation review
Zinc at AREDS doses interacts with copper status and can upset the stomach. High-dose beta carotene is unsafe in smokers, which is why AREDS2 removed it. We also ask directly about any Ayurvedic or herbal product already in use, including its source, because unregulated preparations carry documented heavy metal risk.
What Ayurvedic Eye Care Offers in Age-Related Macular Degeneration
Ayurvedic practice approaches the eye through digestion, circulation, sleep, heat and dryness, and daily routine. Applied honestly in AMD, that framework overlaps substantially with what the nutrition and cardiovascular evidence already recommends. The dietary emphasis on fresh vegetables, ghee and other whole fats, regular meal timing, and adequate sleep is not in conflict with a Mediterranean pattern. Where it adds value is adherence: patients who have been handed a supplement bottle and a pamphlet often do better with a structured daily routine they can actually follow.
There is no randomized trial of any classical Ayurvedic formulation for macular degeneration. A search of the published literature for Ayurvedic interventions in AMD returns no controlled trials of clinical outcomes. Acupuncture has been examined in a systematic review of randomized trials in AMD, and the pooled evidence was limited by small samples and methodological weakness rather than being convincingly positive. Saffron has drawn interest and has been reviewed for ocular effects, but the trial base remains small and short. We describe these accurately rather than overstating them.
- Structured support for the dietary pattern with the best observational evidence in AMD, translated into food you will actually eat
- Help sustaining an AREDS2 regimen your retina specialist recommended, including managing zinc-related stomach upset and timing
- Smoking cessation support integrated into the eye visit rather than deferred elsewhere
- Ocular surface comfort, including dryness and irritation that often coexist with AMD in this age group
- Sleep, stress, and routine work that supports blood pressure and glycemic control
- Glare management, lighting advice, and contrast strategies for reading
- Coordination with low vision rehabilitation, which has randomized evidence and is under-referred
- A clear, written escalation plan so a distortion symptom triggers a same-week retina appointment
What it cannot do should be stated without hedging. Ayurvedic therapy does not shrink drusen, does not reverse geographic atrophy, does not regenerate photoreceptors, and does not treat choroidal neovascularization. Netra tarpana and similar external therapies do not reach the macula in any meaningful pharmacologic sense. If anyone tells you an oil, ghee, decoction, or eye wash can replace anti-VEGF injections in wet AMD, they are describing something that does not exist, and acting on that advice causes permanent loss.
Where Ayurvedic Therapy Fits Alongside Anti-VEGF Treatment and AREDS2 Supplementation
Never in place of an injection schedule
If you are receiving anti-VEGF therapy for wet AMD, your injection appointments outrank everything else on the calendar. Cochrane reviews of anti-VEGF agents in neovascular AMD found consistent benefit for maintaining vision compared with no treatment, and separate reviews have examined how dosing regimens compare. Missing doses to try an alternative is the most damaging thing a patient with wet AMD can do.
Alongside, not instead of, the AREDS2 formula
If your specialist has recommended the AREDS2 combination, take it. We do not substitute an Ayurvedic preparation for it. Where we help is with tolerability, timing with meals, checking that what you bought matches the studied formulation, and making sure you are not doubling up on zinc from a multivitamin.
Diet as the shared ground
This is where the two systems genuinely meet. Dark leafy greens, orange and yellow vegetables, oily fish two or more times a week, nuts, legumes, olive oil, and low intake of processed meat and refined starch appear in both the AMD cohort literature and in a sensible Ayurvedic dietary plan. We build one plan, not two.
Ocular surface care as supportive therapy
Many people with AMD also have dry eye, blepharitis, or post-injection surface irritation. Gentle lid care, appropriate lubrication, and supervised external Ayurvedic therapies can improve comfort and sometimes clarity of the tear film. That is a real benefit, and it is a surface benefit. It says nothing about the retina.
Monitoring discipline as a clinical intervention
Daily single-eye Amsler testing, knowing the phone number to call, and having a plan for who drives you are unglamorous and they preserve vision. The home monitoring trial in AMD showed that structured surveillance can catch neovascularization at better acuity. We treat that habit as a prescribed part of care.
Function and independence
When central vision has already been lost, the useful questions become lighting, magnification, contrast, eccentric viewing training, and safety at home. Low vision rehabilitation has randomized support for improving vision-related quality of life. We refer for it early rather than treating it as a last resort.
What We Will Not Do
We do not use kajal, surma, or any unregulated Ayurvedic preparation in or around the eye. Independent testing of Ayurvedic products sold online found detectable lead, mercury, or arsenic in a substantial share of samples, and a later scoping review documented the same problem across Indian traditional medicine systems. We do not prescribe home-made eye washes, decoctions, or oils for self-instillation. We do not advise delaying, spacing out, or stopping anti-VEGF injections. We do not claim that any therapy we offer reverses macular damage.
Treatment Options, Honestly Compared
AREDS and AREDS2 supplementation
The original AREDS trial randomized people with intermediate or advanced AMD to high-dose vitamins C and E, beta carotene, and zinc, and found reduced progression to advanced disease. AREDS2 then replaced beta carotene with lutein and zeaxanthin and tested added omega-3 fatty acids. The omega-3 addition did not further reduce progression. Ten-year follow-on analysis supported the lutein and zeaxanthin substitution, chiefly because beta carotene raises lung cancer risk in smokers. Cochrane reviews conclude that these supplements probably slow progression in people who already have AMD, and separately that antioxidant supplements do not prevent AMD in people who do not have it.
Anti-VEGF injections for wet AMD
Intravitreal aflibercept, ranibizumab, brolucizumab, faricimab, and off-label bevacizumab are the standard of care for choroidal neovascularization. They are given into the eye under sterile conditions, usually monthly at first and then on a treat-and-extend or as-needed schedule. Cochrane evidence supports their benefit for preserving vision. Netra Eye Institute does not provide injections; we identify who needs them and get you to a retina specialist quickly.
Complement inhibitors for geographic atrophy
Pegcetacoplan and avacincaptad pegol are intravitreal complement inhibitors approved for geographic atrophy. Phase 3 trials showed slower growth of atrophic lesions on imaging. They do not improve vision and carry a risk of converting dry disease to wet disease, so the decision is a genuine trade-off that belongs with a retina specialist who knows your lesion.
Photodynamic therapy and thermal laser
Verteporfin photodynamic therapy and focal thermal laser were mainstays before anti-VEGF drugs and are now reserved for selected situations such as polypoidal choroidal vasculopathy or certain extrafoveal lesions. They are occasionally combined with injections. We do not provide them, and we mention them so the terminology is not a surprise if a specialist raises it.
Surgical and device options in advanced disease
For end-stage bilateral AMD, an implantable miniature telescope can be placed in one eye to magnify the central image. Submacular surgery and macular translocation are historical procedures rarely used today. These are narrow, carefully selected interventions, not a fallback for anyone dissatisfied with injections.
Lifestyle, diet, and integrative care
Smoking cessation, a Mediterranean-style diet, blood pressure control, weight management, and physical activity carry observational support for lower risk and slower progression. Integrative and Ayurvedic care contributes here, in adherence, comfort, and routine. Its evidence base for AMD specifically is absent at the trial level, and we place it accordingly: useful support, not treatment of the retinal lesion.
Building a Daily Plan for Living With Macular Degeneration
The morning eye check
Pick a fixed time and a fixed place with good light. Cover one eye, look at the Amsler grid or a familiar doorframe or window blind, then switch. Ten seconds per eye. Write the date on a calendar when you do it. The point is not the record, it is that a daily habit makes a new distortion obvious within a day instead of within a month.
Plate composition, not calorie counting
Aim for a large serving of dark leafy greens most days, two or more colors of vegetable at the main meal, oily fish twice a week, a handful of nuts, legumes several times a week, and olive oil as the default fat. Reduce processed meat, deep-fried food, and refined starch. This is the pattern the AMD cohort data points to, and it fits comfortably inside an Ayurvedic meal structure.
Supplement discipline
If you are on an AREDS2 formula, take it with food at the same meal each day. Check that your product matches the studied doses rather than a reduced house version. Do not stack it with a separate zinc supplement. If it causes nausea, tell us before you quit; splitting the dose usually solves it.
Tobacco, without negotiation
If you smoke, this is the highest-value change available to you in AMD. It also removes the beta carotene safety problem entirely. We will help with a quit plan, nicotine replacement referral, and the behavioral side, and we will keep raising it at each visit without lecturing.
Blood pressure, weight, and movement
Take your blood pressure readings seriously and bring the numbers. Most people with AMD are also managing cardiovascular risk, and the two agendas reinforce each other. Regular walking, most days, is enough to count; it also supports sleep and mood, both of which erode when vision declines.
Light, contrast, and glare
Task lighting placed over the shoulder and close to the page is worth more than a stronger prescription in many cases. High-contrast settings on phones and tablets, larger fonts, and a hat or tinted lens outdoors reduce daily strain. Wraparound sunglasses in bright conditions are sensible, though sunlight avoidance alone is not a treatment.
An escalation plan in writing
You should be able to say out loud what you will do if lines bend or a gray patch appears: who to call, which number, what to say, and who will drive you. Put it on the refrigerator. In wet AMD the interval between noticing and being treated is one of the few variables still under your control.
Red Flags That Need Urgent Care
Most AMD changes are slow. A few are not, and some symptoms that feel like AMD are something else entirely. Any of the following should prompt a same-day or next-day call rather than an entry in your monitoring diary.
- New or worsening distortion of straight lines in either eye, even if acuity feels unchanged
- A new gray, dark, or blank patch in central vision appearing over hours or days
- A sudden drop in reading ability in one eye
- A shower of new floaters, flashing lights, or a curtain or shadow moving across the field, which suggests retinal tear or detachment rather than AMD
- Sudden painless loss of vision in one eye, which may indicate vascular occlusion or optic nerve involvement
- Eye pain, redness, marked light sensitivity, or discharge after an intravitreal injection, which can signal endophthalmitis and is an emergency
- Vision loss accompanied by scalp tenderness, jaw pain on chewing, new severe headache, or weight loss in an older adult, which raises concern for giant cell arteritis
- New double vision, facial weakness, slurred speech, or limb weakness, which requires emergency stroke evaluation
- Rapid decline in an eye already treated for wet AMD, which may mean recurrence or a submacular hemorrhage
- Any missed anti-VEGF appointment that has stretched beyond the interval your retina specialist set
If you are unsure whether something counts, call. Nobody at this practice will think less of you for reporting a change that turns out to be nothing. The failure mode that costs vision is the opposite one.
Frequently Asked Questions on Age-Related Macular Degeneration
No. There is no randomized controlled trial of any Ayurvedic formulation or procedure for AMD showing improvement in vision or slowed progression. Damaged photoreceptors and atrophic retinal pigment epithelium do not regenerate. Any claim of reversal is not supported and should be treated as a warning sign about the practitioner making it.
If you have intermediate AMD in one or both eyes, or advanced AMD in one eye, the trial evidence supports it and most retina specialists recommend it. If you only have small drusen or no AMD at all, the evidence does not support taking it for prevention. Check your specific stage with your specialist rather than deciding from a pharmacy shelf.
Dry AMD is the slow accumulation of drusen and, later, patches of atrophy; it is monitored, managed with supplements at the right stage, and in advanced atrophy may be considered for complement inhibitors. Wet AMD means new leaking vessels and is treated with anti-VEGF injections, often urgently. Dry can turn into wet at any time, which is why daily self-checking matters even when your disease is called dry.
External therapies of this kind sit on the ocular surface. They can ease dryness and irritation, which is a genuine comfort benefit, particularly in patients who also have dry eye. They do not deliver anything to the retina in a way that would alter drusen, atrophy, or neovascular activity, and we do not present them as if they did.
In wet AMD, stopping anti-VEGF treatment commonly allows leakage to recur, and scarring or atrophy that develops in the interval does not respond to resumed treatment. Vision lost that way is generally permanent. If injections are difficult because of cost, travel, anxiety, or discomfort, tell your retina specialist so the schedule can be adjusted rather than abandoned.
Selected References for Scientific Support
- Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014. PubMed
- Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001. PubMed
- Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013. PubMed
- Chew EY, Clemons TE, Agron E, et al. Long-term outcomes of adding lutein/zeaxanthin and omega-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 report 28. JAMA Ophthalmol. 2022. PubMed
- Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev. 2023. PubMed
- Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane Database Syst Rev. 2017. PubMed
- Solomon SD, Lindsley K, Vedula SS, et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2019. PubMed
- Li E, Donati S, Lindsley KB, et al. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2020. PubMed
- Heier JS, Lad EM, Holz FG, et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023. PubMed
- Khanani AM, Danzig CJ, Heier JS, et al. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: two-year efficacy and safety results from the GATHER2 phase 3 trial. Ophthalmology. 2026. PubMed
- Merle BMJ, Colijn JM, Cougnard-Gregoire A, et al. Mediterranean diet and incidence of advanced age-related macular degeneration: the EYE-RISK Consortium. Ophthalmology. 2019. PubMed
- Merle BM, Silver RE, Rosner B, et al. Adherence to a Mediterranean diet, genetic susceptibility, and progression to advanced macular degeneration: a prospective cohort study. Am J Clin Nutr. 2015. PubMed
- AREDS2-HOME Study Research Group, Chew EY, Clemons TE, et al. Randomized trial of a home monitoring system for early detection of choroidal neovascularization: Home Monitoring of the Eye (HOME) study. Ophthalmology. 2014. PubMed
- Babaker R, Alzimami L, Al Ameer A, et al. Risk factors for age-related macular degeneration: updated systematic review and meta-analysis. Medicine (Baltimore). 2025. PubMed
- Sun W, Zhao Y, Liao L, et al. Effects of acupuncture on age-related macular degeneration: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2023. PubMed
- Ferrara S, Schloss J. Does Crocus sativus (saffron) have an influence or effect on ocular health: a systematic literature review. J Evid Based Integr Med. 2026. PubMed
- van Nispen RM, Virgili G, Hoeben M, et al. Low vision rehabilitation for better quality of life in visually impaired adults. Cochrane Database Syst Rev. 2020. PubMed
- Saper RB, Phillips RS, Sehgal A, et al. Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet. JAMA. 2008. PubMed
- Mukhopadhyay S, Abraham SE, Holla B, et al. Heavy metals in Indian traditional systems of medicine: a systematic scoping review and recommendations for integrative medicine practice. J Altern Complement Med. 2021. PubMed